Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Current Deferred Revenue (2016 - 2021)

Arcadia Biosciences' Current Deferred Revenue history spans 8 years, with the latest figure at $63000.0 for Q2 2021.

  • For Q2 2021, Current Deferred Revenue changed N/A year-over-year to $63000.0; the TTM value through Jun 2021 reached $63000.0, changed N/A, while the annual FY2020 figure was $8000.0, 80.95% down from the prior year.
  • Current Deferred Revenue reached $63000.0 in Q2 2021 per RKDA's latest filing, roughly flat from $63000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.0 million in Q4 2017 to a low of $8000.0 in Q4 2020.
  • Average Current Deferred Revenue over 5 years is $310875.0, with a median of $88000.0 recorded in 2018.
  • Peak YoY movement for Current Deferred Revenue: plummeted 96.81% in 2019, then surged 270.59% in 2021.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.0 million in 2017, then crashed by 90.4% to $96000.0 in 2018, then crashed by 56.25% to $42000.0 in 2019, then plummeted by 80.95% to $8000.0 in 2020, then surged by 687.5% to $63000.0 in 2021.
  • Per Business Quant, the three most recent readings for RKDA's Current Deferred Revenue are $63000.0 (Q2 2021), $63000.0 (Q1 2021), and $8000.0 (Q4 2020).